|
È޸չ븮 |
ÀÓ»ó ½ºÆä¼È¸®½ºÆ®
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.03 |
|
|
¾ÆÀÌÄÜŬ¸®´ÏÄø®¼Ä¡ |
Entry level Clinical Research Associate (CRA) ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.05 |
|
|
°æºÏ´ëÇб³º´¿ø ÀÓ»ó½ÃÇè¼¾ÅÍ |
°æºÏ´ëÇк´¿ø ÀÓ»ó½ÃÇè¼¾ÅÍ ºÐ¼®½Ç ¿¬±¸¿ø
´ë±¸ ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.31 |
|
|
Çѱ¹Æ丵Á¦¾à(ÁÖ) |
Medical CRA °è¾àÁ÷ (ASAP-2021.10 2³â)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.14 |
|
|
½Ã¹ÍÄÚ¸®¾Æ |
[½Ã¹ÍÄÚ¸®¾Æ] Senior Medical Writer ä¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
09.10 |
|
|
IQVIA¢â |
IQVIA CRA¸ðÁý°ø°í
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.29 |
|
|
(ÁÖ)¿Ã¸®ºêÇコÄɾî |
ÀÓ»ó »ó´ã Äݼ¾ÅÍ Á¤±ÔÁ÷ ä¿ë (½ÅÀÔÁö¿ø°¡´É)
°æ±â ¿ëÀνà | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.19 |
|
|
IQVIA¢â |
Manager, Global Site Activation (Regulatory and Start-up
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
08.11 |
|
|
(ÁÖ)¾¾¿£¾Ë¸®¼Ä¡ |
¹ÙÀÌ¿À, ÀÓ»ó CRO [¾¾¿£¾Ë¸®¼Ä¡] ºÎ»ê »çºÎ¼Ò CRA ä¿ë
ºÎ»ê ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.13 |
|
|
Á¸½¼¾ØµåÁ¸½¼ |
[Çѱ¹¾á¼¾] 2023 »ó¹Ý±â ±Û·Î¹ú ÀÓ»ó °æ·Â»ç¿ø ´ë±Ô¸ð °øä
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.30 |
|
|
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ |
¸ÞµðÇïÇÁ¶óÀÎ ÀÓ»ó½ÃÇè CRA °æ·Â&½ÅÀÔ Ã¤¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.30 |
|
|
(ÁÖ)À¯Æ¿·º½º |
ºñÀÓ»óÆÀ(¿¬±¸) ä¿ë
¼¿ï ±Ýõ±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.17 |
|
|
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ |
¸ÞµðÇïÇÁ¶óÀÎ Àӻ󿬱¸ CR °æ·Â&½ÅÀÔ Ã¤¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.22 |
|
|
(ÁÖ)¾¾¿£¾Ë¸®¼Ä¡ |
¢ß¾¾¿£¾Ë¸®¼Ä¡ Research ºÎ»ê »ç¹«¼Ò CO ÆÀ [°æ·Â] CRA ä
ºÎ»ê µ¿±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.27 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] ½ÅÀÔ CRA ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.05 |
|